UroGen Pharma to Participate at Upcoming May 2024 Investor Conferences

2024-05-07

Citizens JMP Life Sciences Conference H.C. Wainwright 2nd Annual BioConnect Conference PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences Conference – May 14, 2024 Fireside Chat: May 14, 2024 at 10:00am ET Location: New York, NY Webcast Registration Link: Here H.C. Wainwright BioConnect Conference – May 20, 2024 Fireside Chat: May 20, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit or follow us on X (Twitter), @UroGenPharma. View source version on businesswire.com: Contacts INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@urogen.com 609-460-3588 ext. 1093 MEDIA CONTACT: Cindy Romano Director, Corporate Communications cindy.romano@urogen.com 609-460-3583 ext. 1083 Source: UroGen Pharma Ltd. View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构